Dr. Daniel Grossman is a professor of obstetrics, gynecology, and reproductive sciences at the University of California–San Francisco and director of Advancing New Standards in Reproductive Health.
The Food and Drug Administration’s decision to lift restrictions on mifepristone is good news for people in states that allow telemedicine abortion, but means nothing for everyone else.